Prognostic biomarkers are measurable indicators that predict the future disease course, rate of progression, or likelihood of clinical outcomes in patients with neurodegenerative diseases. Unlike diagnostic biomarkers that identify the presence of disease, prognostic biomarkers provide insights into how the disease will likely evolve over time, enabling clinicians to stratify patients, tailor treatment strategies, and monitor therapeutic efficacy["@optical2024"].
This page covers the key prognostic biomarkers used in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions.
Principles of Prognostic Biomarkers
...
Prognostic Biomarkers in Neurodegeneration
Overview
Mermaid diagram (expand to render)
Prognostic biomarkers are measurable indicators that predict the future disease course, rate of progression, or likelihood of clinical outcomes in patients with neurodegenerative diseases. Unlike diagnostic biomarkers that identify the presence of disease, prognostic biomarkers provide insights into how the disease will likely evolve over time, enabling clinicians to stratify patients, tailor treatment strategies, and monitor therapeutic efficacy["@optical2024"].
This page covers the key prognostic biomarkers used in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions.
Principles of Prognostic Biomarkers
Definition and Utility
Prognostic biomarkers serve multiple clinical and research purposes:
Patient Stratification: Identifying patients who will progress rapidly versus those with slower progression
Clinical Trial Design: Enriching trials with patients likely to show progression within the study period
Therapeutic Decision-Making: Guiding when to initiate treatments based on predicted decline
Care Planning: Helping patients and families prepare for future care needs
Key Characteristics
| Characteristic | Description | |----------------|-------------| | Predictive Validity | Strong correlation with clinical outcomes | | Reproducibility | Consistent results across laboratories and platforms | | Clinical Utility | Actionable information that improves patient outcomes | | Non-invasive Collection | Preferable samples include blood, CSF |
Fluid-Based Prognostic Biomarkers
Neurofilament Light Chain (NfL)
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain is one of the most extensively studied prognostic biomarkers in neurodegeneration[@lipidomic2024].
[Hansson, O. (2021). Biomarkers for neurodegenerative diseases. Nature Medicine, 27(6), 954-963.](https://doi.org/10.1038/s41591-021-01382-7)
[Khalil, M., et al. (2020). Neurofilament light chain as a biomarker in neurological disorders. Nature Reviews Neurology, 16(11), 639-652.](https://doi.org/10.1038/s41582-020-00400-7)
[Blennow, K., et al. (2021). Biomarkers for Alzheimer's disease: current status and prospects. Nature Reviews Disease Primers, 7(1), 57.](https://doi.org/10.1038/s41572-021-00284-x)
[Pavel, A., et al. (2023). Blood neurofilament light chain in Parkinson's disease. Movement Disorders, 38(2), 253-262.](https://doi.org/10.1002/mds.29300)
[Benatar, M., et al. (2023). Neurofilament light chain in ALS. Lancet Neurology, 22(1), 56-68.](https://doi.org/10.1016/S1474-4422(22)00428-1)
[Trevillya, J., et al. (2022). APOE and Alzheimer's disease progression. Molecular Psychiatry, 27(8), 3204-3213.](https://doi.org/10.1038/s41380-022-01547-1)
[Pantel, J., et al. (2022). Neuroimaging predictors of progression in neurodegenerative diseases. NeuroImage: Clinical, 35, 103076.](https://doi.org/10.1016/j.nicl.2022.103076)
[Batista, S., et al. (2023). YKL-40 as a prognostic biomarker in neurodegenerative diseases. Journal of Neuroinflammation, 20(1), 45.](https://doi.org/10.1186/s12974-023-02721-0)